Safety and Effectiveness of Regdanvimab for COVID-19 Treatment: A Phase 4 Post-marketing Surveillance Study Conducted in South Korea.

Lee JY, Bu SH, Song E, Cho S, Yu S, Kim J, Kym S, Seo KW, Kwon KT, Kim JY, Kim S, Ahn K, Jung N, Lee Y, Jung Y, Hwang C, Park SW

Open source

DOI: 10.1007/s40121-023-00859-1
Published: 2023 Oct
Container: Infectious diseases and therapy
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s40121-023-00859-1,
  title = {Safety and Effectiveness of Regdanvimab for COVID-19 Treatment: A Phase 4 Post-marketing Surveillance Study Conducted in South Korea.},
  author = {Lee JY and Bu SH and Song E and Cho S and Yu S and Kim J and Kym S and Seo KW and Kwon KT and Kim JY and Kim S and Ahn K and Jung N and Lee Y and Jung Y and Hwang C and Park SW},
  year = {2023},
  journal = {Infectious diseases and therapy},
  doi = {10.1007/s40121-023-00859-1},
  url = {https://doi.org/10.1007/s40121-023-00859-1}
}

RIS

TY  - JOUR
TI  - Safety and Effectiveness of Regdanvimab for COVID-19 Treatment: A Phase 4 Post-marketing Surveillance Study Conducted in South Korea.
AU  - Lee JY
AU  - Bu SH
AU  - Song E
AU  - Cho S
AU  - Yu S
AU  - Kim J
AU  - Kym S
AU  - Seo KW
AU  - Kwon KT
AU  - Kim JY
AU  - Kim S
AU  - Ahn K
AU  - Jung N
AU  - Lee Y
AU  - Jung Y
AU  - Hwang C
AU  - Park SW
PY  - 2023
JO  - Infectious diseases and therapy
DO  - 10.1007/s40121-023-00859-1
UR  - https://doi.org/10.1007/s40121-023-00859-1
ER  -

APA

JY, L., SH, B., E, S., S, C., S, Y., J, K., S, K., KW, S., KT, K., JY, K., S, K., K, A., N, J., Y, L., Y, J., C, H., & SW, P. (2023). Safety and Effectiveness of Regdanvimab for COVID-19 Treatment: A Phase 4 Post-marketing Surveillance Study Conducted in South Korea.. Infectious diseases and therapy. https://doi.org/10.1007/s40121-023-00859-1

Source records

pubmed · retrieved 2026-09-26T22:45:25.233Z
europe-pmc · retrieved 2026-09-26T22:45:25.242Z
doaj · retrieved 2026-09-26T22:45:25.249Z